Shuai Qian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8120049/publications.pdf

Version: 2024-02-01

54 papers	1,415 citations	331670 21 h-index	345221 36 g-index
54 all docs	54 docs citations	54 times ranked	1712 citing authors

#	Article	IF	Citations
1	Biopharmaceutics classification and intestinal absorption study of apigenin. International Journal of Pharmaceutics, 2012, 436, 311-317.	5.2	147
2	Coamorphous Lurasidone Hydrochlorideâ€“Saccharin with Charge-Assisted Hydrogen Bonding Interaction Shows Improved Physical Stability and Enhanced Dissolution with pH-Independent Solubility Behavior. Crystal Growth and Design, 2015, 15, 2920-2928.	3.0	115
3	Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement. European Journal of Pharmaceutical Sciences, 2013, 48, 740-747.	4.0	104
4	Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. International Journal of Pharmaceutics, 2014, 468, 272-282.	5.2	94
5	Coformer selection based on degradation pathway of drugs: A case study of adefovir dipivoxilâ€“saccharin and adefovir dipivoxilâ€“nicotinamide cocrystals. International Journal of Pharmaceutics, 2012, 438, 327-335.	5.2	63
6	Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update. Expert Opinion on Drug Delivery, 2020, 17, 1411-1435.	5.0	54
7	Mechanistic Study on Complexation-Induced Spring and Hover Dissolution Behavior of Ibuprofen-Nicotinamide Cocrystal. Crystal Growth and Design, 2018, 18, 7343-7355.	3.0	50
8	Sustained release and enhanced bioavailability of injectable scutellarin-loaded bovine serum albumin nanoparticles. International Journal of Pharmaceutics, 2014, 476, 142-148.	5.2	43
9	Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin. European Journal of Pharmaceutical Sciences, 2019, 129, 21-30.	4.0	40
10	Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride. Molecular Pharmaceutics, 2020, 17, 84-97.	4.6	34
11	Bioavailability enhancement of glucosamine hydrochloride by chitosan. International Journal of Pharmaceutics, 2013, 455, 365-373.	5.2	33
12	A novel drugâ€“drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide. RSC Advances, 2020, 10, 565-583.	3.6	33
13	Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption. Journal of Clinical Pharmacology, 2012, 52, 1343-1349.	2.0	32
14	Physicochemical and Pharmacokinetic Characterization of a Spray-Dried Cefpodoxime Proxetil Nanosuspension. Chemical and Pharmaceutical Bulletin, 2010, 58, 912-917.	1.3	31
15	Gel formation of puerarin and mechanistic study during its cooling process. International Journal of Pharmaceutics, 2018, 548, 625-635.	5.2	29
16	Cubosomes with surface cross-linked chitosan exhibit sustained release and bioavailability enhancement for vinpocetine. RSC Advances, 2019, 9, 6287-6298.	3.6	29
17	Charge-assisted intermolecular hydrogen bond formed in coamorphous system is important to relieve the pH-dependent solubility behavior of lurasidone hydrochloride. RSC Advances, 2016, 6, 106396-106412.	3.6	26
18	Charge-assisted bond N + H mediates the gelation of amorphous lurasidone hydrochloride during dissolution. International Journal of Pharmaceutics, 2017, 518, 335-341.	5.2	26

#	Article	IF	Citations
19	Preparation and Physicochemical and Pharmacokinetic Characterization of Ginkgo Lactone Nanosuspensions for Antiplatelet Aggregation. Journal of Pharmaceutical Sciences, 2016, 105, 242-249.	3.3	24
20	Synthesis, biological activity, and biopharmaceutical characterization of tacrine dimers as acetylcholinesterase inhibitors. International Journal of Pharmaceutics, 2014, 477, 442-453.	5.2	22
21	Pharmacokinetics and Disposition of Various Drug Loaded Liposomes. Current Drug Metabolism, 2012, 13, 372-395.	1.2	21
22	Gel Formation Induced Slow Dissolution of Amorphous Indomethacin. Pharmaceutical Research, 2019, 36, 159.	3.5	21
23	Deaggregation and Crystallization Inhibition by Small Amount of Polymer Addition for a Co-Amorphous Curcumin-Magnolol System. Pharmaceutics, 2021, 13, 1725.	4.5	21
24	Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats. Journal of Medicinal Chemistry, 2018, 61, 1474-1482.	6.4	20
25	Physicochemical and pharmacokinetic characterization of a spray-dried malotilate emulsion. International Journal of Pharmaceutics, 2011, 414, 186-192.	5.2	18
26	Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats. Journal of Pharmaceutical and Biomedical Analysis, 2012, 61, 57-63.	2.8	18
27	Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. Life Sciences, 2018, 207, 428-435.	4.3	18
28	Coamorphization combined with complexation enhances dissolution of lurasidone hydrochloride and puerarin with synchronized release. International Journal of Pharmaceutics, 2020, 588, 119793.	5.2	17
29	Quantification of meclizine in human plasma by high performance liquid chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 95-99.	2.3	16
30	Enhanced oral bioavailability of docetaxel in rats combined with myricetin: In situ and in vivo evidences. European Journal of Pharmaceutical Sciences, 2017, 101, 71-79.	4.0	15
31	Characterization and Stability of Amorphous Tadalafil and Four Crystalline Polymorphs. Chemical and Pharmaceutical Bulletin, 2018, 66, 1114-1121.	1.3	15
32	Zolpidem Mucoadhesive Formulations for Intranasal Delivery: Characterization, InÂVitro Permeability, Pharmacokinetics, and Nasal Ciliotoxicity in Rats. Journal of Pharmaceutical Sciences, 2016, 105, 2840-2847.	3.3	14
33	Modification of hygroscopicity and tabletability of <scp>l</scp>-carnitine by a cocrystallization technique. CrystEngComm, 2021, 23, 2138-2149.	2.6	14
34	Characterization of two polymorphs of lornoxicam. Journal of Pharmacy and Pharmacology, 2012, 65, 44-52.	2.4	13
35	Identification of novel adefovir dipivoxil-saccharin cocrystal polymorphs and their thermodynamic polymorphic transformations. International Journal of Pharmaceutics, 2019, 566, 361-370.	5.2	13
36	Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 833-854.	3.3	12

#	Article	IF	Citations
37	Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1491-1508.	3.3	12
38	Effects of Temperature and Ionic Strength of Dissolution Medium on the Gelation of Amorphous Lurasidone Hydrochloride. Pharmaceutical Research, 2019, 36, 72.	3.5	12
39	Improving Tabletability of Excipients by Metal-Organic Framework-Based Cocrystallization: a Study of Mannitol and CaCl2. Pharmaceutical Research, 2020, 37, 130.	3.5	12
40	The effects of Glycyrrhizae uralenis and its major bioactive components on pharmacokinetics of daphnetin in Cortex daphnes in rats. Journal of Ethnopharmacology, 2014, 154, 584-592.	4.1	11
41	Mechanistic insight into gel-induced aggregation of amorphous curcumin during dissolution process. European Journal of Pharmaceutical Sciences, 2022, 170, 106083.	4.0	11
42	Pharmacokinetics and brain uptake of HIV-1 replication inhibitor DB213 in Sprague-Dawley rats. Journal of Pharmaceutical and Biomedical Analysis, 2016, 125, 41-47.	2.8	10
43	Competitive cocrystallization and its application in the separation of flavonoids. IUCrJ, 2021, 8, 195-207.	2.2	10
44	Pharmacokinetic Comparison Between the Long-Term Anesthetized, Short-Term Anesthetized and Conscious Rat Models in Nasal Drug Delivery. Pharmaceutical Research, 2014, 31, 2107-2123.	3.5	9
45	Puerarin-Na Chelate Hydrate Simultaneously Improves Dissolution and Mechanical Behavior. Molecular Pharmaceutics, 2021, 18, 2507-2520.	4.6	7
46	Charge-assisted bond and molecular self-assembly drive the gelation of lenvatinib mesylate. International Journal of Pharmaceutics, 2021, 607, 121019.	5.2	5
47	Compound coverage enhancement of electrospray ionization mass spectrometry through the addition of a homemade needle. Analyst, The, 2013, 138, 1772.	3.5	4
48	Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals. Pharmaceutical Research, 2021, 38, 1777-1791.	3.5	4
49	Improvement of the Pharmacological Properties of Maize RIP by Cysteine-Specific PEGylation. Toxins, 2016, 8, 298.	3.4	3
50	Insights into Cocrystallization and Coamorphization Engineering Techniques in the Delivery of Traditional Chinese Medicine: Formation Mechanism, Solid-State Characterization, and Improved Pharmaceutical Properties. Crystal Growth and Design, 2022, 22, 5110-5134.	3.0	3
51	Thermodynamic and kinetic studies on the polymorphic transformations of puerarin hydrates. International Journal of Pharmaceutics, 2021, 597, 120374.	5.2	2
52	The bending behavior of an l-phenylalanine monohydrate soft crystal via reversible hydrogen bond rupture and remodeling. Physical Chemistry Chemical Physics, 2022, 24, 3216-3221.	2.8	2
53	Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted â^†pKa Rule. Pharmaceutical Research, 0, , .	3.5	2
54	Cocrystallization and Coamorphization for Druggability Enhancement of Chinese Medicines. , 2021, , 239-276.		1